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entered a pre-study, open-label, run-in phases of the trial programme, of which 1,094 patients were randomised to double-blind treatment. A total of 398 patients were randomised to placebo and 696 to carvedilol.
Study design
The trial programme consisted of four multi-centre, double-blind, randomised studies. The duration of the treatment ranged from 1 day to 15.1 months (median: 6.5 months). Eighty-five per cent of the placebo-treated patients, and 89% of the carvedilol-treated patients, continued with the study medication until the end of the trial. The patients were followed-up for 15 months.
Analysis of effectiveness
The authors stated that the analysis was conducted on an intention to treat basis. The authors also reported that the pretreatment characteristics were similar in the two groups. The risk of hospitalisation due to congestive heart failure, myocardial infarction, intermediate coronary syndrome, or other reasons, was recorded in the study. Differences in the hospitalisation risk were plotted using Kaplan-Meier methods, and tested using a Cox proportional hazards regression model.
Effectiveness results
Carvedilol reduced the risk of being hospitalised at least once for any reason by 29% (95% confidence interval, CI: 8 -46, p=0.034). Similarly, carvedilol reduced the risk of hospitalisation by 28% (95% CI: 2 -46) for cardiovascular causes and by 38% (95% CI: 2 -61) for heart failure. Carvedilol also reduced the mean number of hospitalisations per patient for any reason by 25% (p=0.003).
Clinical conclusions
The authors stated that carvedilol both reduced the risk of clinical deterioration in patients with heart failure, and lessened the severity of illness among those patients who were hospitalised.
Modelling
Models were used to assign costs to the types of hospitalisation that were evaluated in the trial. These cost-prediction models used data from routinely collected hospitalisation records in acute-care hospitals in the USA.
Measure of benefits used in the economic analysis
No summary measure of benefit was used in the paper. The analysis therefore used a cost-consequences approach.
Direct costs
The cost per hospitalisation was estimated using cost-prediction models developed using a hospital administrative database. The costs included the time spent in various hospital units, the services used, and the total hospitalisation costs. The authors selected a master sample of hospital admissions for heart failure using International Classification of Diseases (ICD-9) codes for heart failure in the database. The ICD-9 codes were also used to develop cost prediction models for four different hospitalisation diagnoses. These were "congestive heart failure", "myocardial infarction", "intermediate coronary syndrome" and "other or unspecified angina pectoris". These modes were applied to the resource use identified in the trial programme. All the costs were adjusted to 1994 levels. The costs were, appropriately, not discounted because discounting was irrelevant.
Statistical analysis of costs
The difference in resource use between treatment with carvedilol or placebo was analysed using the Wilcoxon rank sum test. Cost-variance analyses were used to evaluate whether the reduction in the hospital costs was due to fewer admissions or to a reduced cost per stay. exercised in the interpretation of these data. The authors also pointed out that only inpatient costs were included in the analysis and that the other costs were excluded. For example, the cost of carvedilol and associated monitoring costs. The costs were appropriately analysed using a non-parametric test. However, the paper would have benefited from presenting confidence intervals around the estimated differences in the average costs.
Other issues
The study included an appropriate patient sample. In addition, it measured relevant outcomes and applied appropriate analysis techniques. In terms of comparisons with other studies, the authors stated that the results from this study confirmed the findings of other studies of carvedilol in heart failure. Patients from several centres in several states were included in the study. Thus, the results are likely to be generalisable to patients in NYHA classes II to IV in the USA. The results are also likely to be generalisable to patients with similar characteristics in other settings, where heart failure is treated in a similar fashion.
